BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32106160)

  • 1. TOXICITY AND EFFICACY OF INTRAVITREAL MELPHALAN FOR RETINOBLASTOMA: 25 µg Versus 30 µg.
    Liao A; Hsieh T; Francis JH; Lavery JA; Mauguen A; Brodie SE; Abramson DH
    Retina; 2021 Jan; 41(1):208-212. PubMed ID: 32106160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study.
    Francis JH; Schaiquevich P; Buitrago E; Del Sole MJ; Zapata G; Croxatto JO; Marr BP; Brodie SE; Berra A; Chantada GL; Abramson DH
    Ophthalmology; 2014 Sep; 121(9):1810-7. PubMed ID: 24819859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Toxicity of Intravitreous Chemotherapy for Retinoblastoma: Four-Year Experience.
    Francis JH; Brodie SE; Marr B; Zabor EC; Mondesire-Crump I; Abramson DH
    Ophthalmology; 2017 Apr; 124(4):488-495. PubMed ID: 28089679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal melphalan hydrochloride vs propylene glycol-free melphalan for retinoblastoma vitreous seeds: Efficacy, toxicity and stability in rabbits models and patients.
    Bogan CM; Pierce JM; Doss SD; Tao YK; Chen SC; Boyd KL; Liao A; Hsieh T; Abramson DH; Francis JH; Friedman DL; Richmond A; Daniels AB
    Exp Eye Res; 2021 Mar; 204():108439. PubMed ID: 33444583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results.
    Shields CL; Manjandavida FP; Arepalli S; Kaliki S; Lally SE; Shields JA
    JAMA Ophthalmol; 2014 Mar; 132(3):319-25. PubMed ID: 24407202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma.
    Berry JL; Bechtold M; Shah S; Zolfaghari E; Reid M; Jubran R; Kim JW
    Ophthalmology; 2017 Dec; 124(12):1817-1825. PubMed ID: 28655537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model.
    Kaczmarek JV; Bogan CM; Pierce JM; Tao YK; Chen SC; Liu Q; Liu X; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Friedman DL; Richmond A; Daniels AB
    Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):8. PubMed ID: 34757417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal chemotherapy in the management of vitreous disease in retinoblastoma.
    Kiratli H; Koç İ; Varan A; Akyüz C
    Eur J Ophthalmol; 2017 Jun; 27(4):423-427. PubMed ID: 28106239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INTRAVITREOUS CHEMOTHERAPY FOR ACTIVE VITREOUS SEEDING FROM RETINOBLASTOMA: Outcomes After 192 Consecutive Injections. The 2015 Howard Naquin Lecture.
    Shields CL; Douglass AM; Beggache M; Say EA; Shields JA
    Retina; 2016 Jun; 36(6):1184-90. PubMed ID: 26630319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma.
    Ghassemi F; Shields CL; Ghadimi H; Khodabandeh A; Roohipoor R
    JAMA Ophthalmol; 2014 Aug; 132(8):936-41. PubMed ID: 24789622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal Lower-Dose (20 µg) Melphalan for Persistent or Recurrent Retinoblastoma Vitreous Seeds.
    Tuncer S; Balcı Ö; Tanyıldız B; Kebudi R; Shields CL
    Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):942-8. PubMed ID: 26469234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan.
    Francis JH; Abramson DH; Gaillard MC; Marr BP; Beck-Popovic M; Munier FL
    Ophthalmology; 2015 Jun; 122(6):1173-9. PubMed ID: 25795478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients.
    Xue K; Ren H; Meng F; Zhang R; Qian J
    BMC Ophthalmol; 2019 Feb; 19(1):61. PubMed ID: 30808420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications.
    Munier FL; Gaillard MC; Balmer A; Soliman S; Podilsky G; Moulin AP; Beck-Popovic M
    Br J Ophthalmol; 2012 Aug; 96(8):1078-83. PubMed ID: 22694968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined intravitreal melphalan and intravenous/intra-arterial chemotherapy for retinoblastoma with vitreous seeds.
    Lee JH; Han JW; Hahn SM; Lyu CJ; Kim DJ; Lee SC
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):391-4. PubMed ID: 26511530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma.
    Ghassemi F; Shields CL
    Arch Ophthalmol; 2012 Oct; 130(10):1268-71. PubMed ID: 23044940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity to intravitreal melphalan in a patient with retinoblastoma.
    Solaz-Ruiz MG; Pérez LA; Cauto-Picazo C; Barranco-González H; Pascual-Camps I; España-Gregori E
    Rom J Ophthalmol; 2023; 67(3):305-308. PubMed ID: 37876503
    [No Abstract]   [Full Text] [Related]  

  • 18. Pathological findings in enucleated eyes after intravitreal melphalan injection.
    Ghassemi F; Amoli FA
    Int Ophthalmol; 2014 Jun; 34(3):533-40. PubMed ID: 24043335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and toxicity of second-course ophthalmic artery chemosurgery for retinoblastoma.
    Francis JH; Abramson DH; Gobin YP; Marr BP; Tendler I; Brodie SE; Dunkel IJ
    Ophthalmology; 2015 May; 122(5):1016-22. PubMed ID: 25616769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study.
    Bogan CM; Kaczmarek JV; Pierce JM; Chen SC; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Nadelmann JB; Liao A; Hsieh T; Abramson DH; Francis JH; Friedman DL; Richmond A; Daniels AB
    Br J Ophthalmol; 2022 Feb; 106(2):288-296. PubMed ID: 33972235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.